Insmed Files Countersuit Against Tercica

Law360, New York (October 17, 2006, 12:00 AM EDT) -- A long-running battle over drugs for children with short stature took another turn Friday, when Insmed Inc. countersued rival pharmaceutical company Tercica Inc. for false advertising.

In the claim, filed with the U.S. District Court in Richmond, Va., Insmed alleged that Tercica made false and misleading statements regarding both companies’ hormone replacement drugs, which are used to treat patients with severe primary IGF-I deficiency.

“At issue are statements made by Tercica that Insmed believes are likely to mislead customers into believing that [Tercica’s drug] Increlex is...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.